Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Analgesic effect of intravenous lidocaine in chronic inflammatory bowel disease with abdominal pain
2023-508224-35-01Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Liège
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of lidocaine in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis (2 arms), sponsored by Centre Hospitalier Universitaire de Liège. Primary endpoints: Reduction in background abdominal pain scores, Decrease in frequency of hyperalgesia flare-ups and 1 more. Planned start Jul 2024; status: authorised.
02
Drugs
lidocaine
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on 2023-508224-35-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508224-35-01.